Sygnature Discovery announced the set-up of a state-of-the-art Early Candidate Developability Screening Group. The new service line expands the company’s portfolio into formal preclinical drug development. A new world-class facility with complementary chemistry, in vitro and in vivo pharmacology and DMPK capabilities will be operational in September 2021.
Sygnature Discovery will tailor strategies for each individual API and through access to well-equipped preformulation and formulation development laboratories rapidly and unbiasedly identify the most phase-appropriate development approach.
Dr Richard Weaver SVP of Pre-Clinical Development commented on the new service offering: “There is an increasing need for engaging the formulation scientist at an earlier stage and most importantly having constant and iterative dialogue with the DMPK, Pharmacology and Chemistry teams. Inadequate bioavailability in many late-stage research and development compounds is a real modern-day challenge. There is often a way forward if the reasons for the poor bioavailability are not due to DMPK reasons. A key part of this process is making the human efficacious dose prediction range as early as possible and feeding this information to the formulating scientists, along with the theoretical gains that can be made”.
Dr Paul Overton, Chief Operating Officer, continued “Our expansion of the value chain into early CMC development will be of significant benefit to our customers as we partner with them from early drug discovery. The expansion into the formulation space fits with our strategic goal of being able to have the line of sight of the clinic and feeding this into our earliest discussions with the customer to maximize their chance of clinical success”.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox!
Sign up now!